



RECEIVED

AUG 02 2002

TECH CENTER 1600/2900

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Maria Glucksmann et al.

Serial No.: 10/075987

Filed: February 13, 2002

For: 14273 RECEPTOR, A NOVEL G-PROTEIN
COUPLED RECEPTOR

Attorney Docket No.: MNI-204CP2DV2

Group Art Unit: 1646

Examiner: Brannock, M.

COPY OF PAPERS
ORIGINALLY FILED

Commissioner for Patents
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

July 24, 2002

Date of Signature and of Mail Deposit

By:

Maria C. Laccotripe, Ph.D.

Attorney for Applicant/s

Limited Recognition Under 37 CFR

§10.9(b)

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their attorney are aware of the following patents, publications or other information, which are cited on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these forms for the Examiner's consideration.


The present application is a divisional application of application no. 09/261,599 filed on February 26, 1999 (Atty. Docket No. MNI-204CP2), Pending, which in turn is a continuation-in part of copending U.S. Patent Application Serial No. 09/223,538, filed December 30, 1998, and entitled

"14273 RECEPTOR, A NOVEL G-PROTEIN COUPLED RECEPTOR", which is a continuation-in-part of copending U.S. Patent Application Serial No. 09/107,761, filed June 30, 1998, and entitled "14273 RECEPTOR, A NOVEL G-PROTEIN COUPLED RECEPTOR". All references listed on the enclosed PTO Form 1449 have been previously cited by or submitted to the Office in the prior application, and, in accordance with 37 CFR §1.98(d), copies of these references are not enclosed herewith, but will be provided upon request.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP



Maria C. Laccotripe, Ph.D.
Attorney for Applicant
Limited Recognition Under 37 CFR §10.9(b)

28 State Street
Boston, MA 02109
(617) 227-7400

Date: July 24, 2002

GAD/AEM/MCL/kvj
Enclosures

APPLICANT FACSIMILE OF FORM PTO-1449

REV 7-80

U.S. DEPARTMENT OF
COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO

MNI-204CP2DV2

SERIAL NO.

10/075987

LIST OF PUBLICATIONS CITED BY APPLICANT
(Use several sheets if necessary)

APPLICANT

Maria Glucksmann et al.

FILING DATE

February 13, 2002

GROUP

AUG 02 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	5,576,296	11/96	Barfai et al.	514	13	
	A2	5,756,460	05/98	Evans et al.	514	12	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	A3	WO 94/01548 A2	01/94	PCT				
	A4	WO 96/14331 A1	07/99	PCT				
	A5	WO 98/15570 A1	04/98	PCT				
	A6	WO 99/38972 A2	01/99	PCT				
	A7	WO 99/33982 A2	07/99	PCT				
	A8	WO 00/00611 A2	01/00	PCT				

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)


	A9	BLAST Search vs. SwissProt, Genbank, Dbest and Patents Databases.
	A10	EMBL Accession No. AA030752 for mi31h04.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone IMAGE:465175 5', mRNA sequence.
	A11	EMBL Accession No. AA413234 for ve94g10.r1 Knowles Solter mouse blastocyst B1 Mus musculus cDNA clone IMAGE:833922 5' similar to gb:X71129 ELECTRON TRANSFER FLAVOPROTEIN BETA-SUBUNIT (HUMAN);, mRNA sequence.
	A12	SwissProt Accession No. P41145, sequence alignment.
	A13	Bowie, J.U. et al., "Deciphering the message in protein sequences: tolerance to amino acid substitutions," <i>Science</i> . 1990 Mar 16; 247(4948):1306-10.
	A14	Bowles, K.R. et al., "Genomic characterization of the human peptidyl-prolyl-cis-trans-isomerase, mitochondrial precursor gene: assessment of its role in familial dilated cardiomyopathy," <i>Hum Genet</i> . 1999 Dec; 105(6):582-6.
	A15	Brown J.H. et al., "Pathways and roadblocks in muscarinic receptor-mediated growth regulation," <i>Life Sci</i> . 1997; 60(13-14):1077-84.
	A16	Chatelain et al., "Cardiac Ischaemia: Possibilities for Future Drug Therapy," <i>Eur. J. Med. Chem</i> . 1997; 32:687-707.
	A17	Glennon, P.E. et al., "Cellular mechanisms of cardiac hypertrophy," <i>Br Heart J</i> . 1995 Jun;73(6):496-9.

Examiner

Date Considered

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY OF PAPERS
ORIGINALLY FILED

APPLICANT FACSIMILE OF FORM PTO-1449

REV 7-80

U.S. DEPARTMENT OF
COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO

MNI-057CP2DV2

SERIAL NO.

10/075987

LIST OF PUBLICATIONS CITED BY APPLICANT
(Use several sheets if necessary)

APPLICANT

Maria Glucksmann et al.

FILING DATE

February 13, 2002

GROUP

AUG 02 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

B1	Lee, N.H. et al., "Molecular Biology of G-Protein-Coupled Receptors," <i>Drug News and Perspectives</i> . 1993;6(7):488-97.
B2	MacLellan, W.R. et al., "Death by design. Programmed cell death in cardiovascular biology and disease," <i>Circ Res</i> . 1997 Aug;81(2):137-44.
B3	Mills, A. et al., "Orphan seven transmembrane domain receptors: reversing pharmacology," <i>Trends Biotechnol</i> . 1994 Feb;12(2):47-9.
B4	Ngo, J.T., "Computational Complexity, Protein Structure Prediction and the Levinthal Paradox," in <i>The Protein Folding Problem and Tertiary Structure Predictions</i> . K. Merz and S. Legrand, Eds. Birkhauser, Boston, 1994.
B5	Oliveira, L. et al., "A common Motif in G-Protein-Coupled Seven Transmembrane Helix Receptors," <i>Journal of Computer-Aided Molecular Design</i> . 1993; 7(6):649-58.
B6	Stadel, J.M., "Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery," <i>Trends Pharmacol Sci</i> . 1997 Nov;18(11):430-7.
B7	Wells, J.A., "Additivity of mutational effects in proteins," <i>Biochemistry</i> . 1990 Sep 18;29(37):8509-17.
B8	Yamazaki, T., "The renin-angiotensin system and cardiac hypertrophy." <i>Heart</i> . 1996 Nov;76(3 Suppl 3):33-5.
Examiner	
Date Considered	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

COPY OF PAPERS
ORIGINALLY FILED